Enliven Therapeutics is a clinical-stage precision oncology company developing allosteric small-molecule therapies targeting validated oncology pathways, with a focus on menin inhibitors for acute myeloid leukemia (AML) and other genetically defined cancers. Its lead program ELVN-001 is being developed for patients with NPM1-mutant and KMT2A-rearranged leukemias.
ELVN-001 Phase 1 dose-escalation update in AML
ELVN-002 initial Phase 1 data in HER2-mutant solid tumors
Enliven Therapeutics said the FDA aligned on the ENABLE-2 Phase 3 trial design for relcobatinib (ELVN-001) in previously treated chronic myeloid leukemia.